Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4576 to 4590 of 8212 results

  1. Natural history of progression to colorectal cancer in people at increased risk:- What is the natural history of progression to colorectal cancer in people with inflammatory bowel disease (IBD) or adenomas?

    Recommendation ID CG118/2 Question Natural history of progression to colorectal cancer in people at increased risk:- What is the natural

  2. What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up?

    Recommendation ID NG131/5 Question What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term

  3. NICE concluded that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema secondary to retinal vein occlusion should be conducted.

    Recommendation ID TA283/1 Question NICE concluded that further research directly comparing the clinical and cost effectiveness of ranibizumab

  4. NICE considered that if enzalutamide is used in routine clinical practice for treating hormone relapsed metastatic prostate cancer that has been previously treated with abiraterone, data should be collected on resource use and overall survival.

    Recommendation ID TA316/2 Question NICE considered that if enzalutamide is used in routine clinical practice for treating hormone relapsed

  5. NICE considered that more research is needed to establish the treatment sequence for vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma.

    Recommendation ID TA319/1 Question NICE considered that more research is needed to establish the treatment sequence for vemurafenib and

  6. NICE considered that there is an important need for head-to-head comparisons between biological treatments for psoriatic arthritis, particularly in people for whom treatment with tumour necrosis factor (TNF) alpha inhibitors has been unsuccessful.

    Recommendation ID TA340/1 Question NICE considered that there is an important need for head-to-head comparisons between biological treatments

  7. NICE encourages further research into faecal microbiota transplant for C. difficile infection, specifically to investigate optimal dosage, mode of administration and choice of donor.

    Recommendation ID IPG485/1 Question NICE encourages further research into faecal microbiota transplant for C. difficile infection, specifically